XNAS
TMDX
Market cap4.80bUSD
Jun 20, Last price
123.56USD
1D
-0.35%
1Q
78.94%
IPO
398.23%
Name
Transmedics Group Inc
Chart & Performance
P/E
117.88
P/S
9.47
EPS
1.05
Div Yield, %
—
Shrs. gr., 5y
19.91%
Rev. gr., 5y
79.64%
Revenues
442m
+82.74%
Net income
35m
P
CFO
49m
P
Earnings
Jul 29, 2025
Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 441,540 82.74% | 241,623 158.53% | 93,459 208.83% | ||||||
Cost of revenue | 404,044 | 243,138 | 124,896 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 37,496 | (1,515) | (31,437) | ||||||
NOPBT Margin | 8.49% | ||||||||
Operating Taxes | 316 | (1,643) | 66 | ||||||
Tax Rate | 0.84% | ||||||||
NOPAT | 37,180 | 128 | (31,503) | ||||||
Net income | 35,464 -241.70% | (25,028) -30.92% | (36,231) -18.06% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 955 | 145,977 | |||||||
BB yield | -0.04% | -8.00% | |||||||
| Debt | |||||||||
Debt current | 2,727 | 4,070 | 1,444 | ||||||
Long-term debt | 465,164 | 523,653 | 74,970 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 59,372 | ||||||||
Net debt | 131,241 | 132,911 | (125,268) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 48,803 | (13,028) | (45,817) | ||||||
CAPEX | (151,847) | (11,907) | |||||||
Cash from investing activities | (129,303) | (193,953) | 54,513 | ||||||
Cash from financing activities | 22,874 | 400,418 | 167,927 | ||||||
FCF | (113,186) | (192,089) | (66,048) | ||||||
| Balance | |||||||||
Cash | 336,650 | 394,812 | 201,182 | ||||||
Long term investments | 500 | ||||||||
Excess cash | 314,573 | 382,731 | 197,009 | ||||||
Stockholders' equity | 228,603 | 137,202 | 187,375 | ||||||
Invested Capital | 518,287 | 517,981 | 67,555 | ||||||
ROIC | 7.18% | 0.04% | |||||||
ROCE | 5.02% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 35,217 | 32,517 | 29,557 | ||||||
Price | 62.35 -21.01% | 78.93 27.88% | 61.72 222.13% | ||||||
Market cap | 2,195,770 -14.45% | 2,566,596 40.69% | 1,824,235 244.76% | ||||||
EV | 2,327,011 | 2,699,507 | 1,698,967 | ||||||
EBITDA | 37,496 | 6,662 | (27,959) | ||||||
EV/EBITDA | 62.06 | 405.21 | |||||||
Interest | 14,409 | 10,791 | 3,726 | ||||||
Interest/NOPBT | 38.43% | ||||||||